A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TAVR survival is down in recent years, leaving cardiologists stumped

Researchers tracked recent TAVR data from the STS/ACC TVT Registry, highlighting a "concerning" finding they were unable to explain.

Georgia Lawrence, JD, with ASNC, explains how CMS uses hospital reported data to develop cardiac PET payment rates.

Understanding hospital billing for cardiac PET/CT

Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.

heart doctors and surgeons working together. top cardiology hospitals in the United States.

Cardiothoracic surgeons unite to improve clinical practice guidelines

Four leading cardiothoracic surgery societies have joined forces in the name of developing clinical practice guidelines that are more thorough and consistent.

HeartFlow sharing new data on AI-enabled CAD management at TCT 2024

The California-based company, fresh off receiving expanded Medicare coverage and a new Category I CPT code for its AI offerings, will have a significant presence at TCT 2024. 

Erin Stevens explained the technical aspects for a successful PET program. #ASNC #thinkPET

Key steps to implementing a successful PET program

Getting technologists, physicians and administrators to work together is a crucial part of any PET program. Research is also essential. Cardiovascular Business spoke to a specialist on the topic to learn more.

CVRx banner

New Category I CPT codes announced for treating heart failure with implantable Barostim device

Baroreflex activation therapy with the Barostim device from CVRx has received new CPT codes from the American Medical Association. The codes go into effect in January 2026.

Shockwave Newsletter

MedAxiom partners with Shockwave Medical to support ‘game-changing’ IVL technology

Shockwave Medical, now a part of Johnson & Johnson MedTech, continues to gain momentum among U.S. cardiologists. According to one MedAxiom executive, IVL "brings an important dimension to cardiovascular care for patients with calcified coronary and peripheral arterial disease."

Advanced device-based therapies are associated with significant benefits for heart failure patients and should be used alongside traditional pharmaceutical treatments, according to a new scientific statement from the Heart Failure Society of America (HFSA). The statement, published in full in the Journal of Cardiac Failure, examines a number of new-look medical devices that have emerged in recent years as additional ways to treat heart failure.

Cardiologists make case for increasing use of device-based therapies for heart failure

Device-based therapies can provide considerable value for heart failure patients when used alongside traditional pharmaceutical treatments. A new HFSA scientific statement outlines the benefits of these devices, urging care teams to implement them into daily practice.